argenx Delivers 60% Year-over-Year Growth in a Strong First Half of 2026
argenx reported $1.5 billion in second-quarter global product net sales, representing 60% year-over-year growth and 17% growth over the prior quarter. The company also launched VYVGART and VYVGART Hytrulo in seronegative generalized myasthenia gravis, extending patient reach to all gMG serotypes.
argenx expects registrational readouts in myositis and multifocal motor neuropathy as it continues to build its immunology pipeline.
